MedicalExpo e-Magazine - #17 – Deep Inside the HeartMedicalExpo e-Magazine

The Smart Magazine About Medical Technology Innovations

Deep in the Heart




Three-D printed models of newborns’ hearts, biodegradable stents, cardiac MRI showing the heart in seven dimensions and innovative wearable cardiac devices—this new edition of MedicalExpo e-magazine goes deep inside the human heart to unveil the latest trends in cardiology

 

We also interviewed an expert from the U.S. Food and Drug Administration to understand how they regulate 3D printed devices, and we offer you a taste of new healthcare IT products showcased at the conhIT Conference this month in Berlin.

Smart People
The most striking thing about the 3D models, when you have them in your hands, is how small and complex a newborn baby’s heart can be
Babies' Hearts 3D Models (Courtesy of 3D Print Lab)

/

The Phoenix Children’s Heart Center created a couple of years ago its own in-house Cardiac 3D Print Lab. Dr. Justin Ryan, lead research scientist at the lab, and Dr. Stephen Pophal, interventional cardiologist, explained to MedicalExpo how 3D printed models of babies’ hearts represent a tremendous aid in surgical...


Wallikids Banner
Hot Topic
Developers hope bioresorbable scaffolds will avoid some of the long-term problems with permanent stents
Bioresorbable Scaffold (Courtesy of Abbott Vascular)

A medical breakthrough, bioresorbable scaffolds are designed to repair and restore diseased coronary vessels. They are intended to deliver results similar to drug-eluting stents before being completely resorbed by the body. Despite some limitations, they usher in a new era for interventional cardiology.

 

A couple of square millimeters is all the space oxygen-rich blood has to push its way through the lumen of a coronary artery.

Plaque lesions along the way do not exactly facilitate the journey and may lead to Coronary Artery Disease (CAD), with its typical symptoms and complications, including angina and myocardial infarction. So ever since researchers and cardiologists have learned about the pathogenesis of CAD, they have been working on materials and techniques to open up lesions and restore blood flow and arterial function.

Following angioplasty-balloons, bare-metal stents (BMS) and drug-eluting stents (DES), the latest addition to the interventional cardiologist’s toolbox is the bioresorbable scaffold, aka bioabsorbable or biodegradable stent, such as Abbott Vascular’s Absorb, or Elixir’s DESolve.

Dissolving Several Months After Implantation

Instead of remaining permanently inside the body, these devices aim at propping up diseased vessels by providing radial strength just as long as it is really necessary, before beginning to gradually degrade several months after implantation. Developers hope this will avoid some of the long-term problems with permanent stents, particularly important for younger patients. 

Dr. Petra Guhr, Manager Marketing Communication DACH, at Abbott Vascular, Germany told MedicalExpo:

Dr. Petra Guhr (Courtesy of Abbott Vascular)

Dr. Petra Guhr (Courtesy of Abbott Vascular)

The dream has always been to find a temporary solution for a temporary problem, giving blood vessels a chance to bounce back to their natural state.

“This is comparable to putting a cast on a broken leg and removing it after the bone is fully healed,” she said. Abbott Vascular has been developing the Absorb Bioresorbable Vascular Scaffold System (BVS) since the early 2000s, winning CE certification in 2010 and a positive review by the U.S. Food and Drug Administration Advisory Committee in 2016.

Absorb BVS consists of bioresorbable scaffold and coating elements, both made of polylactide acids (PLA). Such materials are also used in absorbable surgical sutures and other medical applications, and are the key constituents of Elixir’s DESolve and the ancestor of all bioresorbable scaffolds, the Igaki-Tamai stent, as well. “However, one PLA is not necessarily identical to another. Only the exact composition of the PLA and the design of the scaffold determine its essential properties, such as the speed at which the scaffold dissolves.”

Raising Questions

Furthermore, just like Abbott’s industry standard drug-eluting stent, Xience, Absorb BVS releases Everolimus to prevent restenosis, and has an enhanced delivery system to facilitate use. According to Guhr, to date about 125,000 patients have been treated with Absorb worldwide, 13,000 of them in the context of clinical studies.

The Absorb BVS passed the recent ABSORB III non-inferiority trial, using an Xience DES control group. However, although not considered statistically significant, slightly more patients in the Absorb group (7.8%) experienced target lesion failure than in the Xience group (6.1%). This raises the question of whether the new bioresorbable technology might be inferior to established stents after all.

Dr. Sharma (Courtesy of Dr. Samin K. Sharma)

Dr. Sharma (Courtesy of Dr. Samin K. Sharma)

Dr. Samin K. Sharma, Professor of Cardiology at the Mount Sinai Hospital, New York City, has worked in interventional cardiology since the 1980ies and has treated patients as part of the ABSORB III trial. He explained in an interview with MedicalExpo:

I think that this is just work in process. In my opinion, interventionalists have to understand this as a proof of concept – that this is a great technology, it is here to stay, and we need to make it better.

Learning More About This Technology

“I know that a lot of people are sitting on the fence and that there is a borderline enthusiasm on this issue, but I am very enthusiastic. I have used it and I think that will be good for us,” explained Sharma. His current clinical experience with bioresorbable scaffolds includes about 75 patients in the U.S. and India.

We cannot get them in complex lesions yet, because we need to learn how this technology is going to behave in complex lesions. So until we have that, I would say, that we should reserve it for the non-complex, noncalcified lesions.

Might bioresorbable scaffolds replace DES as the gold standard for treating Acute Coronary Syndrome (ACS) in the future? Sharma thinks it will be used as “a specialty item”, particularly because of some limitations, such as when treating lesions around coronary artery bifurcations or in very large vessels.

“Once we improve techniques and maybe get second generations of biodegradable stents, at the peak time my prediction is, that it could take up to 40 percent of the DES-market.”

 


Doctor 2 0 MedicalExpo Partnership
Innovation Focus
ViosWorks offers a way of encoding all of the diagnostic information at once
Screen capture of a 4D flow acquisition of a full chest (Courtesy of Arterys)

/

Accelerated visualization, depicting 3D cardiac anatomy, function, and flow analysis, with cloud-based image processing, are key advances of ViosWorks, a major innovation for cardiac MRI. Although ViosWorks is not yet commercially available, GE Healthcare and the San Francisco start-up Arterys showcased it at the...


The Micra Transcatheter Pacing System (Courtesy of Medtronic)

The Micra Transcatheter Pacing System is 2.5 cm long and 93 percent smaller than conventional pacemakers, making it the smallest in the world, according to...



The MoMe Kardia (Courtesy of InfoBionic)

/

The MoMe Kardia by InfoBionic, which received clearance from the U.S. Food and Drug Administration in March, is a remote patient monitoring system designed to...



  • Join our 155,000 subscribers

  • 3D printed exoskeletal cast (Courtesy of Evill Design)

    /

    With the rise of 3D printing in the healthcare sector, there are ongoing discussions about the U.S. Food and Drug Administration’s regulation strategy concerning 3D printed devices. MedicalExpo talked with Matthew Di Prima, Head of the Additive Manufacturing Working Group at the FDA’s Center for Radiological Devices and Health.

     

    MedicalExpo e-magazine: How does the FDA control the quality of 3D printed devices?

    Matthew Di Prima: Devices constructed using 3D printing technology are subject to the same regulatory review standards as devices constructed using traditional manufacturing practices.

    However, 3D printing techniques have different technical considerations than standard manufacturing. Furthermore, traditional manufacturing settings have design controls and systems, such as for complaint handling, that 3D printing settings may not have. That is why devices manufactured using 3D printing technology may need additional or different testing than what is normally performed for products that are manufactured using traditional (subtractive) techniques. As 3D printing technology develops, FDA may provide further clarity on quality control issues such as material qualifications and sterility.

    Devices manufactured using 3D printing technology may need additional or different testing than what is normally performed.

    Regarding 3D printing materials, materials used in formulating or constructing medical products are evaluated for safety or effectiveness within the context of overall safety and effectiveness of the medical product for its intended use. Note that FDA does not clear or approve materials for medical devices and/or products, it clears or approves finalized medical devices and/or products.

    Software used in conjunction with 3D printing is regulated through the same pathways as other medical device software. The specific pathway will depend on the intended use and risk level.

    ME e-magazine: 3D printing often relates to personalized medicine. How does it impact the FDA certification process?

    Matthew Di Prima: Patient-matched devices (a form of personalized medicine) or devices made from a common design and adjusted to more closely fit a patient’s anatomy or physiology, are currently regulated through FDA’s existing regulatory pathways. The device manufacturer must still show the devices meet the safety and effectiveness criteria as required by the type and class of that device.

    ME e-magazine: How do you deal with medical manufacturing facility equipped with 3D printers?

    FDA is considering regulatory options for individuals who would like to print medical devices at home.

    Matthew Di Prima: 3D printers to fabricate medical devices are generally considered to be manufacturing equipment subject to Good Manufacturing Practice/Quality System regulations but are not considered to be medical devices themselves.

    The objects that are fabricated by these printers are considered to be medical devices if they are intended for use as specified in the Act (FFDCA) or are labeled or promoted for such use.

    FDA is also currently considering regulatory options for individuals who would like to print medical devices at home or other user sites and anticipates providing information in the near future.

    3D Printer at the Wake Forest Institute for Regenerative Medicine (Courtesy of WFIRM)

    3D Printer at the Wake Forest Institute for Regenerative Medicine (Courtesy of WFIRM)

    ME e-magazine: 3D printing opens new challenges in terms of biocompatibility, sterility and cleaning. How should these challenges be handled?

    Matthew Di Prima: Biocompatibility, sterility, and cleaning are concerns with all medical devices. The FDA held a workshop in October of 2014 on 3D printing in which these concerns were discussed with industry and academia.

    Additionally, the FDA is conducting research to better understand how these challenges vary for different 3D printing technologies and is working to develop a draft technical guide to assist industry in addressing these concerns. The device manufacturer must show that their product has no safety or effectiveness issues regarding biocompatibility, sterility and cleaning.

    Check out our previous editions about 3D Printing: issue #14 “3D Printed Humans” and issue #15 “3D Printing in Surgery“.

     


    The Custo watch (Courtesy of Customed)

    /

    Customed, German provider of IT solutions for medical technology and cardiology, revealed at the conhIT Conference in Berlin from 19-21 April its new Custo...


    The HeartLight system (Courtesy of CardioFocus)

    The U.S. company CardioFocus just won approval from the Food and Drug Administration for its HeartLight endoscopic cardiac ablation system for treating...



    Improving Video Management in the Operating Room (Courtesy of EIZO)

    The German manufacturer EIZO presented new operating room software at the conhIT Conference in Berlin from 19-21 April. CuratOR Caliop offers centralized...



    Dragon Medical One reduces the time spent by physicians typing (Courtesy of Nuance)

    Saving time always matters. In hospitals, it means saving lives. Nuance Communications, supplier of speech and imaging technologies, offers with Dragon Medical One dictation technology that may significantly reduce the time spent by physicians typing patient records.

     

    Dragon Medical One is a secured cloud-based speech recognition platform developed for fast, easy, mobile patient documentation.

    “We offer up to 22 different languages, including different accents such as Swiss or Austrian German,” explained Milko Jovanoski, International Marketing Manager for Healthcare at Nuance, in an interview with MedicalExpo“Users can also operate the system with voice navigation. Studies show that doctors can save 30 minutes or more a day like this.” Dictionaries for different fields of medicine are provided, be it radiology, surgery or internal medicine.

    Studies show that doctors can save 30 minutes or more a day like this.

    Dragon Medical One turns any workstation into a “dictation station.” It can be installed on a variety of devices, including laptops, smartphones, workstations and tablets. The installation takes only a few minutes and updates are installed automatically. Voice profile training is not necessary; the technology includes accent detection and automatic microphone calibration. Vocabulary can be personalized and individual user profiles improve the quality of the records.

    Enhancing Physician Mobility

    The software is compatible with most leading electronic patient records systems (EHR) such as Epic, Cerner, eClinicalWorks, athenahealth, MEDITECH, GE and McKesson. In addition, 256-bit encryption channels using TLS protocols ensure that voice files are securely transferred to the EHR.

    Integration of Nuance’s narrative capture solution into clinical work is easy. The doctor just opens the client application, places the cursor where the text should appear and dictates notes or patient history. It is transcribed in real time and transferred to the cloud and into the EHR. “Like this staff that works elsewhere or takes over after the change of shift can access the data almost simultaneously,” says Jovanoski. “Time consuming handovers become dispensable.”

    The software is compatible with most leading electronic patient records systems (EHR).

    Dragon Medical One enhances physician mobility and clinical workflow beyond hospital walls. It can be used in the office, at home or in the car. However, the private cloud solution currently is only available in the U.S. market.

    The same product is offered in Europe as Dragon Medical 360 Direct. In the European version, access to data is only granted to users who are directly connected to the central hospital server.

    Nuance’s Dragon Medical One was showcased at the Berlin conhIT Conference, from 19-21 April.

     


    CONTRIBUTORS



    Guy Ramsay

    Guy Ramsay is a South African medical writer.


    Read More

    Celia Sampol

    Celia Sampol has been a journalist for 15 years. She worked in Brussels and Washington for national medias (Agence France Presse, Liberation). She’s now the editor-in-chief of MedicalExpo e-magazine.


    Read More

    Laura Newman

    Laura Newman is a New York-based medical writer who writes frequently about medical technological advances and health policy.


    Read More

    Kristina Müller

    Kristina Müller is a freelance journalist writing mainly about nautical and medical issues.


    Read More

    Kerry Sheridan

    Kerry Sheridan is an authors and health journalist based in Miami, Florida.


    Read More

    Christina Kuhrcke

    Christina Kuhrcke is a Berlin-based freelance journalist, doctor and digital storyteller.


    Read More

    Style Switcher

    Highlight Color:

                   

    Backgrounds:

                        

    You can also set your own colors or background from the Admin Panel.